TScan Therapeutics, Inc. Common Stock

Day range

$0.18 – $0.20

Open

$0.20

Prev close

$0.20

Volume

800.64K

Market cap

$13.77M

Shares out

63.5M

P/E

—

P/S

1.91

P/B

0.20

P/FCF

—

ROE

-170.6%

ROA

-68.7%

Debt/Equity

0.47

Div yield

0.00%

As of Oct 23, 2026

• Director departureOct 16, 2026

  On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") and each committee thereof, in each case effective as of October 13, 2026 (the "Resignations"). Neither Mr. Nicholson's nor Dr. Gruia's resignation was a result of any disagreement with the Company on any matter relating to the Company's operations, practices or policies.

• Executive officer departureSep 30, 2026

  As previously disclosed in the Company's Current Report on Form 8-K filed September 2, 2026, in connection with a strategic reorganization of the Company, it was agreed that ... Chrystal Louis, M.D., MPH, would cease to serve as the Company's Chief Medical Officer.

• Executive compensation changeSep 11, 2026

  On September 8, 2026, the Compensation Committee of the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") approved a retention program designed to retain the employees required to support the Company, including a key employee retention program (the "Retention Program") that provides for cash awards and the potential future grant of equity-based awards to certain key employees of the Company, including Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, and Zoran Zdraveski, JD, Ph.D., the Company's Chief Legal and Strategy Officer.

• Restructuring planSep 2, 2026

  The strategic reorganization is expected to produce cumulative cost savings of $55.0 million through the end of 2027 and includes a workforce reduction of approximately 75%.

Days to cover

3.3

Short interest

2.49M

Avg volume

764.43K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
  positiveGlobeNewswire Inc.· Jun 22, 2026
• TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
  positiveGlobeNewswire Inc.· May 6, 2026
• TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
  positiveGlobeNewswire Inc.· Apr 8, 2026
• TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
  positiveGlobeNewswire Inc.· Feb 26, 2026
• TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
  positiveGlobeNewswire Inc.· Dec 6, 2025